CEL-SCI CORPORATION Operating Lease Right-of-Use Assets
CEL-SCI CORPORATION (CVM) had Operating Lease Right-of-Use Assets of $1.44 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.44M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.49M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.54M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.27M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $1.49M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $1.54M 10-Q · filed 2026-02-17 |
| 2025-09-30 | $1.27M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $1.33M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.39M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.44M 10-Q · filed 2025-02-14 |
| 2024-09-30 | $1.50M 10-K · filed 2025-12-29 |
| 2024-06-30 | $1.55M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.60M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.65M 10-Q · filed 2024-02-14 |
| 2023-09-30 | $1.70M 10-K · filed 2025-01-13 |
| 2023-06-30 | $1.75M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $1.79M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $1.84M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $1.88M 10-K · filed 2023-12-21 |
| 2022-06-30 | $1.93M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $1.97M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $2.01M 10-Q · filed 2022-02-11 |
| 2021-09-30 | $2.06M 10-K · filed 2022-12-27 |
| 2021-06-30 | $1.05M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $1.12M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.16M 10-Q · filed 2021-02-12 |
| 2020-09-30 | $1.20M 10-K · filed 2021-12-21 |
| 2020-06-30 | $1.24M 10-Q/A · filed 2020-12-31 |
| 2020-03-31 | $899.51K 10-Q/A · filed 2020-12-30 |
| 2019-12-31 | $945.99K 10-Q/A · filed 2020-12-30 |
| 2019-09-30 | $0.00 10-Q/A · filed 2020-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |